5月23日，从北国边陲黑龙江省传出喜讯，哈电集团哈动股份公司代表我国与黑龙江天狼星电站设备有限公司正式签订了俄罗斯特罗依茨克三大主机供货合同，合同总价约人民币14.5亿元。
俄罗斯历来是全球发电设备制造企业的竞争要地之一，我国发电设备制造企业始终把市场目标之一锁定在俄罗斯。发电设备项目能否在俄罗斯立足，对我国发电设备制造业开拓国际市场具有积极意义。
特罗依茨克2×660兆瓦超临界项目是俄罗斯统一电力系统公司麾下发电二公司投资建设的电站，总承包方是俄罗斯石英—秋明封闭式股份公司（简称石英公司）。
在哈电集团哈动股份公司的统一组织、协调下，哈尔滨三大动力厂和天狼星公司从2007年4月针对该项目进行了技术交流，俄方高层领导多次来访并派遣专家考察。2007年11月，哈动股份公司曲大庄总经理带队赴俄罗斯签署了（俄中电力、天狼星、哈动股份公司）三方开拓俄罗斯市场合作协议；2007年12月签署了（俄中电力、天狼星、哈动股份、东北设计院、黑龙江火电三公司）五方合作协议，标志着开发俄罗斯电站设备市场的“联合体”正式成立，特罗依茨克项目就是“联合体”成员间的第一个合作项目。
特罗依茨克2×660兆瓦超临界项目，总承包方为石英公司，动力岛项目采用招标方式。针对特洛依茨克动力岛项目投标事宜，哈尔滨三大动力厂与天狼星、东北设计院以“联合体”形式共同参与投标。
哈动股份公司张海权副总经理带领哈尔滨三大动力厂有关人员与天狼星公司、俄中电力等单位就特罗依茨克项目进行数次洽谈，于2008年2月29日联合体中标。2008年4月中旬，天狼星公司与石英公司签订动力岛项目设备供货合同。
该项目供货合同的签订，标志着哈电集团代表我国主机设备产品首次打入俄罗斯电力市场，为哈电集团乃至我国发电设备制造企业进一步开拓国际市场奠定了坚实的基础。
Thursday, October 30, 2008
我国发电主机首次打入俄罗斯市场
Tuesday, October 28, 2008
注射用重组人干扰素α2a(酵母)
100万IU/1ml/支
1 毛 状细胞白血病：起始剂量：每日300万国际单位，皮下或肌内注射，16到24周。如耐受性差，则应将每日剂量减少到150万国际单位，或将用药次数改为每 周3次，也可以同时减少剂量和用药次数。 维持剂量：每次300万国际单位，每周3次皮下或肌内注射。如耐受性差，则将每日剂量减少到150万国际单位，每周3次。 疗程：应用该药大约6个月以后，再由医生决定是否对疗效良好的病人继续用药或是对疗效不佳的病人终止用药。注：对血小板减少症病人（血小板计数少于 50×109/L）或有出血危险的病人，建议以皮下注射重组人干扰素α2a。
2 多发性骨髓瘤：应用重组人干扰素α2a300万国际单位，每周3次皮下或肌内注射。根据不同病人的耐受性，可将剂量逐周增加至最大耐收量（900万国际单位）每周3次。除病情迅速发展或耐受性极差外，这一剂量可持续使用。
3 低度恶性非何杰金氏淋巴瘤：重组人干扰素α2a作为化疗的辅助治疗（伴随或不伴随放疗），可以延长低度恶性非何杰金氏淋巴瘤病人的无病生存期和无恶化 生存期。推荐剂量：在常规化疗结束后（伴随或不伴随放疗），每周3次，每次300万国际单位，皮下注射重组人干扰素α2a，至少维持治疗12周。重组人干 扰素α2a的治疗应该在病人从化椃帕品从χ幸换指戳⒓纯迹话闶奔湮瘲放疗后4～6周。重组人干扰素α2a治疗也可伴随常规的化疗方案（如结合环磷酰 胺、强的松、长春新碱和阿霉素）一起进行。以28天为一周期。在第22～26天，皮下或肌内注射重组人干扰素α2a600万国际单位/m2体表面积。重组 人干扰素α2a结合化疗进行治疗时，重组人干扰素α2a的使用应该和化疗同时进行。
4 慢性髓性白血病：重组人干扰素α2a适用于慢性髓性白血病病人。60%处于慢性期的慢性髓性白血病病人，不管是否接受其他治疗，接受重组人干扰素 α2a治疗后可达到血液学缓解。三分之二这类病人在开始接受治疗最近18个月后取得完全的血液学缓解。与细胞毒性化疗不同，重组人干扰素α2a能持续维持 细胞遗传学缓解达40个月以上。推荐剂量：建议对年满18岁或以上的病人作重组人干扰素α2a皮下或肌内注射8～12周，推荐逐渐增加剂量的方案如下： 第1～3天每日300万国际单位 第4～6天每日600万国际单位 第7～84天每日900万国际单位疗程：病人必须接受治疗至少8周，要取得更好的疗效至少需要治疗12周，然后，再由医生决定是否对疗效良好的病人继续用 药或对血液学参数未见任何改善者终止用药。疗效良好的病人应继续用药，直至取得完全的血液学缓解，或者一直用药最多到18个月。所有达到完全血液学缓解的 病人，均应继续以每日900万国际单位（最佳剂量）或以900万国际单位每周3次（最低剂量）进行治疗，以使其在尽可能短的时间内取得细胞遗传学缓解。尽 管有见到开始治疗2年后达到细胞遗传学缓解者，但尚未定出重组人干扰素α2a治疗慢性髓性白血病的最佳疗程。
5 慢性活动性乙型肝炎：重组人干扰素α2a适合治疗伴有HBV?/FONT>DNA、HbeAg及DNA多聚酶阳性等病毒复制标志的成年慢性活动 性乙型肝炎推荐剂量：尚未定出治疗慢性活动性乙型肝炎的最佳治疗方案。通常以500万国际单位每周3次，皮下注射，共用6个月。如用药一个月后病毒复制标 志或HbeAg无下降，则可逐渐加大剂量并可进一步将剂量调整至病人能够耐受的水平，如治疗3～4个月后没有改善，则应考虑停止治疗。儿童：据报道对患有 慢性乙型肝炎的儿童以每平方米体表面积1000万国际单位进行治疗是安全的，但其治疗效果尚未定论。 警告：重组人干扰素α2a对慢性乙型肝炎合并感染人类免疫缺陷病毒（HIV）的病人疗效尚无定论。
6 急慢性丙型肝炎：重组人干扰素α2a适合治疗HCV抗体阳性，谷丙转氨酶（ALT）增高和不伴肝脏失代偿成年慢性丙型肝炎病人。但没有临床和组织学方 面长期好转的依据。起始剂量：以重组人干扰素α2a300～500万国际单位，每周3次，皮下或肌内注射3个月作为诱导治疗。维持剂量：血清谷丙转氨酶正 常的病人需要再以重组人干扰素α2a300万国际单位，每周3次，注射3个月作为完全缓解的巩固治疗。病人血清谷丙转氨酶不正常者必须停止以重组人干扰素 α2a治疗。注：大多数接受了足够治疗后复发的病人会在治疗结束后4个月内复发。
7 尖锐湿疣：以重组人干扰素α2a100～300万国际单位，每周3次，皮下或肌内注射，共1至2个月。或于患处基底部隔日注射100万国际单位，连续3周。
使 用本品后少数病人可有发烧、寒战、乏力、肌痛、厌食等反应。不良反应多在注射48小时后消失。其他可能出现的不良反应有头痛、关节痛、食欲不振、恶心等， 个别病人可能出现粒性白细胞减少、血小板减少等，停药后可恢复。如出现不能忍受的严重不良反应时，应减少剂量或停药，并给予必要的对症治疗。
ALXN新药研发获利丰厚
10/27 01:54 EST
想知道研发新药的成本昂不昂贵，问问Alexion PharmaceuticalsALXN#就知道了。这是一家位于美国康涅狄格州的药物研发公司，15年来已经斥资7.29亿美元进行不同规模的药物研发，主要研究治疗罕见或潜在的致命性血液紊乱疾病药物。去年，公司研发的新药Soliris获批，可以进入美国和欧洲市场进行销售。公司的销售额增长是显而易见的，Soliris作为公司的核心获批产品，公司于周四发布了Soliris连续七个季度营收100%以上的增长率，这是公司连续二个季度利润大涨的丰收季节了。公司因此提高了08年全年的业绩预测，显示对全年业绩增长的信心。Cowen&Co.Soliris分析师Rachel Mc-Minn表示：“对于公司来说，接下来要做的就是稳定运营和高效管理，除此以外别无他法。”
作为治疗阵发性睡眠性血红蛋白尿症（又名PNH）的药物，Soliris是目前唯一获得正式批准的药物。PNH是一种极为罕见的、导致患者全身虚弱并攻击自身血红蛋白细胞的紊乱疾病。患者将出现复发性疼痛、疲劳、肾脏病变以及其它问题。国家健康局数据显示此种疾病的患病率是100万名之中有1到5名。但是 Alexion公司已经未雨绸缪，提前为此做好准备。公司表示目前此种疾病的患病率与日俱增，尤其是在欧洲和美国地区，患者数量已经达到8K到10K名。医生通过监测能够及早发现疾病，在超过15个国家已经有患者开始使用Soliris治疗自己的疾病。
Soliris能够降低血块的数量，维护肾脏正常功能，并回复机体健康。FDA已经在07年3月批准了Soliris上市。欧洲相关监管机构也在今年六月批准此项药物。公司目前站在努力向澳大利亚和日本市场进军。公司总裁兼COO表示：“已经有越来越多国家的内科医生开始使用我们的药物为患者提供治疗。” 公司预计今年在荷兰和英国市场的营收将大涨，因为这些国家的保险商和国家保荐机构已经同意为此种药物支付费用。一年的药物共供应成本为389K。但是公司表示此种药物还能够适用于其它疾病的治疗，包括哮喘病等。公司以及Soliris已经获得了2008年最佳生物科技Galen Prize奖项。
大赛主席Gerald Weissmann表示：“这对于公司的潜在影响是巨大的，事实上公司在药物开发方面的实力无与伦比。”但是此种药物在其它疾病治疗方面的效果目前尚不可知。公司表示将于12月份在American Society of Hematology上发布有关的资料。公司还将开发新药，分析师表示：“很显然，公司的长期发展战略是形成有效地研发管道。”公司成立于1992年，是由耶鲁大学研究院组建的。公司于1996年上市，500名主要员工均来自美国和欧洲。
公司三季度Soliris的销售额达到7120万美元，上个季度货运营收达到530万美元。本季度公司发布的营收为7650万美元。一年前的销售额仅为 2210万美元。周四发布的季报中，每股收益达到0.29美元，同比为亏损0.28美元。公司还提高了08年下半年业绩预测，预测销售额将上涨至 2.56-2.58亿美元。Thomson Reuters分析师预期公司今年的每股收益将上涨0.08美元，09年每股收益将达到0.8美元。
Investor's Business Daily
Biotech Firm's Sales Explode On Drug To Treat Rare Blood Disorder
Friday October 24, 6:07 pm ET
Kevin Harlin Developing new drugs is expensive. Just ask Alexion Pharmaceuticals.
The Cheshire, Conn., drug discovery company has spent a cumulative $729 million over 15 years of research, working mostly on a drug to treat a rare and potentially fatal blood disorder.
Last year, the company finally won critical regulatory approvals to market its drug, Soliris, in the U.S. and Western Europe.
Sales have taken off.
Thanks to Soliris, Alexion's (NasdaqGM:ALXN - News) sole approved product, the company on Thursday reported its seventh consecutive quarter of triple-digit revenue growth. It was the company's second straight profitable quarter.
Alexion increased its revenue guidance and now expects to show its first annual profit in 2008.
"They're doing nothing but executing solidly here," said Rachel McMinn, an analyst at Cowen & Co.
Soliris, the trade name for the drug eculizumab, is the only substance approved to treat paroxysmal nocturnal hemoglobinuria, or PNH.
PNH is a rare, debilitating disease that causes the body to attack its own red blood cells. Patients can suffer recurring pain, fatigue, kidney disease and other problems. The National Institutes of Health thinks that the disease afflicts only one to five people out of a million.
But the company thinks there are 8,000 to 10,000 people in the U.S. and Western Europe with the condition.
The company says awareness of the disease is growing. As that happens, doctors are able to correctly diagnose it more often. There are paying customers in more than 15 countries.
The drug can reduce instances of blood clots, protect kidney function and restore quality of life, the company says.
FDA Nod
Soliris won Food and Drug Administration approvals in March 2007. European regulators cleared it that June. Alexion is now working on approvals in Australia and hopes to begin clinical trials in Japan.
"Simply put, more physicians in more countries are treating more new PNH patients with Soliris," David Keiser, president and chief operating officer, told analysts on a conference call.
Revenue is expected to increase in places such as the Netherlands and Great Britain, where insurers and national health services have agreed to pay for the drug. A year's supply costs about $389,000.
But the company says the drug also shows promise for treating an array of other maladies, including asthma, lupis and age-related macular degeneration.
It's that promise that won Alexion and Soliris the prestigious Galen Prize for best biotechnology product of 2008, according to Gerald Weissmann, the chairman of the award committee.
"It's got enormous impact and potential, and the fact that they've developed this drug is remarkable," said Weissmann, director of the Biotechnology Study Center at New York University's School of Medicine.
But just how useful the drug will be on other conditions isn't clear yet.
The company says it will present some early data at the American Society of Hematology annual meeting in December.
And it's not clear what Alexion will come up with to follow Soliris. It's working on an antibody that could fight such cancers as chronic lymphocytic leukemia, multiple myeloma and ovarian cancer, for instance.
But success there is far from certain, and a long way off.
"Clearly, longer-term, you'd like to see a pipeline developed," McMinn said.
The company was founded in 1992 by Yale University researchers. It went public in 1996. It employs about 500 people, mostly in the U.S. and Europe.
The company sold $71.2 million worth of Soliris in the third quarter and recognized $5.3 million in revenue from shipments made in previous quarters.
That $76.5 million was all the revenue Alexion reported that quarter. A year earlier, it had just $21.8 million in Soliris sales. Some contract revenue brought total income that quarter to $22.1 million.
Earnings Report
Thursday, Alexion reported earnings per share of 29 cents, ex-items, compared with a per-share loss of 28 cents in the year-ago quarter.
Alexion also upped its guidance for the rest of the year. It now expects Soliris sales to be between $256 million and $258 million. It had previously called for sales of $235 million to $245 million.
The higher guidance factors in growing patient numbers and a weaker euro.
The company reported a loss of $1.27 per share last year. Analysts surveyed by Thomson Reuters think it could show an 8-cents-per-share profit this year and an 80-cents-per-share profit in 2009.
In February, the company settled a patent dispute over the technology behind Soliris, paying $10 million to the Oklahoma Medical Research Foundation.
NUVA神经回避系统越小越吃香
10/24 02:23 EST
在经济停滞阶段，投资者往往会慎重考虑高价资本设备的开支，这当然会影响到医疗设备类股的涨跌。作为医疗设备制造商的Nu Vasive(代號:NUVA) 就是拴在这条线上的蚂蚱。尽管这很不公平，因为公司多数销售额来自小型伤口清理工具和器官嫁接，主要适用于侧面和后部入侵伤口最小化的融合手术，多数是由专业医生采用的。分析师表示经济低迷对于背部手术的影响并不大，饱受疼痛侵扰的病人是不会因经济低迷而终止治疗过程的。分析师表示：“当病人决定接受脊椎治疗之时，他们所忍受的疼痛超越了经济衰退带来的影响。”
Nu Vasive上个季度销售额同比增长了50-65%，在本周三收盘后，公司发布了三季度营收同比上涨了73.7%至6690万美元。公司提高08年业绩预测，预测营收将达到2.45-2.47亿美元。尽管销售额并没有取得20%以上的增长，利润则另当别论。由于公司不断对新产品、新技术和外科手术教育进行大量投资，因此仍将出现斥资。三季度公司每股亏损0.21美元，研发投资以及其他成本达到1670万美元。包括研发收费以及一次性收费在内促进公司每股收益增长0.04美元，分析师预计为0.01美元。
但是，公司预测08年每股收益将因此增长0.05-0.07美元，这将是公司首次获得盈利。Thomson Reuters分析师预测09年每股收益为0.46美元。尽管公司算不上是高资本器械生产商，NuVasive的绕开神经手术导航软件系统可谓是价值不菲。这项导航系统能够最大程度上完善脊柱融合手术，能够令神经受损最小化，因此为医院和医疗单位的所青睐。这项技术大大促进了伤口清理产品的销售额增长。每一个疗程能创造1,300至1,700美元的收益。
外科手术设备平均销售额达到500-900美元，植入式生物制剂的每个疗程的利润就更高了，约为11K美元。传奇般的侧面疗程包括在患者侧身开一个小口，而非在背部开一个大口。患因此恢复期往往比普通患者要短。随着越来越多医生开始就此进行培训，公司的营收将出现大幅增长。目前已经有2，000名外科医生就侧面手术接收了培训。
公司目前已经推出的300多件新产品也在促进销售额增长，以及营收的增长。公司本周三宣布将扩展产品组合，并进行相应市场推广，预计将推动明年的营收上涨 40% 。推动新产品线扩展的一个关键因素就是公司今年七月进行的收购战略，收购了生物制剂生产商Osteocel，后者主要生产适用于脊柱手术中的骨髓嫁接仪器。公司表示Osteocel将为09年的尖端生产线创造2800万美元营收。本季度Osteocel已经为公司创造了440万美元营收。公司预测随着生物制剂部门不断扩展，未来几年内的年营收将达到1亿美元。公司在本月引进了新一代神经回避系统——NeuroVision M5，也将创造巨大的营收。
NeuroVision M5作为最新的系统，能够使医生在手术过程中进一步对脊柱和脖颈部位的神经进行监测，最大程度上避免损伤神经。分析师表示：“NeuroVision M5的运用已经被荒废多年了，因此亟待更新换代。”公司的CEO Alex Lukianov表示，这项新系统将被赋予更新的理念和特点。
而在价值70亿美元的世界脊柱医疗市场中，竞争已经愈演愈烈，Medtronic(代號:MDT)的Sofamor Danek产品就占据50%以上市场份额的巨头。另一个行业巨头包括Johnson & Johnson (代號:JNJ)的DePuy，以及Stryker(代號:SYK)。分析师表示NuVasive占据6%的美国市场份额，几乎所有的销售都是针对美国市场的。但是公司将在未来几年中进行市场扩展，包括欧洲和亚洲。三季度公司在一项产品诉讼中赔偿了600K美元，分析师预计四季度的诉讼开支将达到400万美元，09年将达到500万美元。
Investor's Business Daily
When In Pain, Back Surgery Doesn't Wait For Economic Recovery
Thursday October 23, 6:05 pm ET
Marilyn Alva In a stalled economy, investors might be rightfully concerned about weak spending for high-ticket capital gear. That's certainly been a concern for followers of medical-equipment stocks.
Some might lump medical-device maker NuVasive in that boat. That would be unfair.
Most of NuVasive's (NasdaqGS:NUVA - News) sales are from dozens of small disposal tools and grafts used to perform a minimally invasive lateral back-fusion surgery it developed with specialists.
Analysts say the economy doesn't much matter when it comes to back surgeries. People in pain don't want to put off procedures, and reimbursements don't stop when the economy does.
"By the time people make a decision to have this spine procedure, they are already in such pain it's not something they can delay for economics," said Joanne Wuensch, an analyst with BMO Capital Markets.
Big Sales Growth
NuVasive's year-over-year sales have grown 50% to 65% the last eight quarters.
On Wednesday after the market close, the firm reported that third-quarter revenue soared 73.7% from the earlier year to $66.9 million.
And it upped its 2008 revenue guidance to $245 million to $247 million from $238 million to $240 million earlier.
Though sales have been growing in double digits, profits are another story. Investments in new products, surgeon education, new sales reps and technology have kept the young company in the red.
NuVasive reported a 21-cent loss in the third quarter, citing $16.7 million in research and development costs and other expenses. Excluding the research charge and other one-time costs, NuVasive earned 4 cents a share. Analysts expected a profit of 1 cent a share.
However, it forecast full-year profit of 5 cents to 7 cents a share. It would be the first year of profits. Analysts tracked by Thomson Reuters estimate earnings of 46 cents in 2009.
Though it doesn't consider itself a big-ticket capital equipment company, NuVasive does make a costly software-driven nerve avoidance navigation system that enables surgeons to perform its unique spinal-fusion surgery.
The company gives those units away to hospitals to encourage them to adopt the minimally invasive procedure, since it helps spur sales for its disposable products.
Each procedure generates $1,300 to $1,700 from disposable products, the company says. Surgical instruments add $500 to $900.
The implants and biologics that are needed to complete each procedure generate even more -- almost $11,000 per procedure.
The novel lateral procedure involves making small incisions in a patient's side rather than larger ones in the back or front. Recovery time is shorter since surgeons don't have to cut into much muscle or bone, and costs are lower.
As more physicians are trained to perform the operation, NuVasive stands to gain added revenue. Almost 2,000 surgeons have been trained to perform the lateral surgery.
New products and a growing sales force -- now numbering 300 -- also help drive revenue growth, analysts say. The firm stated on Wednesday that an expanding product portfolio and geographic expansion will lead to revenue growth of nearly 40% next year.
One key new product line comes from the July acquisition of the biologics product line Osteocel -- bone-marrow grafts used in spine-fusion surgery. NuVasive said Osteocel would add $28 million to 2009's top line. Osteocel kicked in $4.4 million in the third quarter.
NuVasive expects its expanded biologics division to generate $100 million in revenue annually in the next several years.
NuVasive's introduction this month of a next-generation nerve-avoidance system -- NeuroVision M5 -- also will help generate new revenue, analysts say. The new system allows surgeons to navigate further up the spine to the neck area so that they can perform minimally invasive cervical procedures as well.
The M5 "is a big deal," said analyst Jose Haresco of Brean Murray Carret. "The NeuroVision has already been out a few years, and it needed an upgrade."
Chief Executive Alex Lukianov says the new system will be able to handle additional features as they are developed. "This moves us another three years ahead of our competitors," he said in a phone interview.
Competition in the $7 billion worldwide spine market is intense, dominated by Medtronic's (NYSE:MDT - News) Sofamor Danek, which has about 50% market share. Other larger players include Johnson & Johnson's (NYSE:JNJ - News) DePuy unit, Synthes and Stryker (NYSE:SYK - News).
Half-Price Sale
Lukianov says the Osteocel grafts give his firm an edge over medical-equipment giant Medtronic because they sell for about half the price of Medtronic's version.
Haresco wrote in a client note that smaller, more specialized players such as NuVasive and Kyphon have been taking market share from their bigger rivals.
Lukianov says NuVasive holds 6% market share in the U.S., up from about 4% last year. Almost all of NuVasive's sales are in the U.S., but Lukianov says the company plans to expand next year in key markets in Europe and Asia.
Meanwhile, some analysts are concerned over legal expenses from a patent infringement lawsuit brought by Medtronic on some of NuVasive's products.
In the third quarter, NuVasive spent $600,000 in legal expenses to defend itself and officials say they expect to spend $1 million in the fourth quarter and $4 million to $5 million in 2009.
LMIA收购狂潮如火如荼
一次成功的收购战略往往能够令一家濒临破产的公司起死回生，LMI Aerospace(代號:LMIA)就是一例。最为一家金属片生产商，LMI Aerospace主要为航空和航天工业提供零部件，公司近期推出了一系列的收购增长战略。从上世纪90年代起，飞机生产商Boeing(代號:BA) 就拥有LMI Aerospace很大一部分的业务，直到2001年公司上市之后，公司业务扩展至军工领域，引发新一轮抢购狂潮。LMI Aerospace成立于58年以前，近十年来积极开展业务多元化战略和一系列大规模的收购交易。公司的喷气式飞机业务目前已经涉足商业航空器板块，后者已经成为公司最大的销售额创造者。
LMI Aerospace自去年六月以来就通过进行最大规模的收购交易不断扩展业务能力。目前公司已经斥资6500万美元收购San Diego-based D3 Technologies，后者是一家一流的设计和技术维护公司。分析师表示：“对于San Diego-based D3 Technologies的收购战略是公司的一项大举措。” D3 Technologies现在已经将公司业务扩展至整个技术维护板块，提供一整套包括建筑、系统以及工具设计服务，项目管理支持，物流以及航空舰队维护服务等在内。在此项收购之前，公司仅染指机翼或驾驶舱门窗领域的业务，但是并不包括设计和制造。分析师表示：“目前，对于D3 Technologies的收购已经使得我们能够涉足航空器的食品链供应缓解。”同时此项收购交易还使得公司能够更多的零部件设计，包括整个机身的零部件制造。
当然，LMI Aerospace并不满足于此，公司还积极地寻找下一个猎物，目前市场中有成千上万的金属片生产商，但是只有LMI Aerospace能够傲视群雄。公司能够弯曲、延展、碾压各种各样的材料，比如铝合金、不锈钢，以及使用于飞机装备的钛合金产品，几乎涵盖了航空器的各个部位，包括机翼、机身、内部构造、齿轮以及其它零部件。此项业务赢得了BA和General Dynamics(代號:GD)的大量订单，包括民用飞机和私人飞机在内。
Investor's Business Daily
Metal Bender Moves Up The Aerospace Food Chain With Acquisition
Tuesday October 21, 5:40 pm ET
Brad Kelly An acquisition can do wonders for a company. Just ask LMI Aerospace. The sheet-metal bender, which makes components for the aerospace industry, designed a growth strategy focused on acquisitions.
Plane maker Boeing (NYSE:BA - News) accounted for a large chunk of LMI's (NasdaqGS:LMIA - News) business in the 1990s before it went on a buying spree in 2001 that expanded the St. Charles, Mo., company into military products and regional jets.
Established 58 years ago, LMI has spent the better part of this decade diversifying its business through various tuck-in acquisitions. The company's corporate-jet business now edges commercial aircraft as its biggest sales generator.
Key Acquisition
It continued expanding capabilities last June by making its most significant acquisition to date. LMI shelled out $65 million in cash to buy San Diego-based D3 Technologies, a premier design and engineering services firm.
"The D3 acquisition filled a strategic hole in LMI's business," said Alex Hamilton, a Jesup & Lamont analyst. "They've done a good job diversifying their operations."
D3 Technologies now comprises LMI's entire engineering services segment, which provides a suite of services such as structural, systems and tool designs, program management support, logistics and fleet maintainability.
Before the acquisition, LMI would get an order to build wing skins or cockpit window frames, but not design them. The D3 acquisition moves the supplier up the food chain, says Tyler Hojo, a Sidoti & Co. analyst.
"Now, with D3 in its fold, LMI is well positioned as a turnkey aerospace systems provider," Hojo said. "(The acquisition) also enables the supplier to bid on bigger projects, such as manufacturing a plane's entire fuselage."
While LMI currently looks for potential acquisition targets -- there are hundreds of mom-and-pop sheet-metal benders available -- it continues to execute on what it does best.
LMI bends, stretches, draws and stamps a myriad of materials, such as aluminum alloys, stainless steel and titanium to outfit aircraft makers with wing skins, fuselage parts, body structures and other interior parts, gears and components.
The manufacturer is busy filling orders for Boeing's passenger planes as well as private jets made by Gulfstream, a division of General Dynamics (NYSE:GD - News). It also supplies metal for Black Hawk helicopters made by Sikorsky, a unit of United Technologies (NYSE:UTX - News).
These projects helped LMI turn in its fourth straight quarter of double-digit sales growth in the April-June period. Revenue soared 91% to $64.9 million. The company expects 2009 sales of $289 million to $304 million. Analysts see revenue of $294.97 million.
Sales at its aerostructures segment rose 23% to $41.6 million, while its engineering services division, consisting entirely of D3 Technologies, recorded $24 million. That was driven in large part by program support for commercial aircraft, in particular Boeing's line of planes.
LMI's military business increased 41% to $11.7 million, due to higher production rates and new awards on the Black Hawk, the company said. Corporate business jets accounted for $14.1 million, up 24% from a year ago, while commercial aircraft sales hit $12.4 million.
Second-quarter earnings jumped 73% to 45 cents a share. Analysts polled by Thomson Reuters expected 39 cents.
Rising commodities and energy costs are not as much a concern to LMI as they would be to other manufacturers. That's because when it bids for a contract, the input costs are already factored in and the cost is passed through to the customer, Hamilton says.
The wars in Afghanistan and Iraq continue to fuel LMI's military business. The Black Hawk carries the lion's share of the load, and the wear and tear is quite high. The company also expects ongoing demand for commercial jets, despite the 45-day strike at Boeing and financial turmoil.
"The Boeing 767 winglet programs and increasing production rates and market share on several Black Hawk models will drive our revenue growth in 2009," CEO Ron Saks said in a post-earnings statement. "These programs are expected to add a minimum of $25 million to $30 million of revenue in 2009."
While LMI will never be taken for a giant in the aerospace industry, its client list includes some of the biggest names in the aerospace industry. But even that might not stave off the problems that have plagued Wall Street.
The credit crunch continues to bite down on the economy, and Hojo expects cancellation rates for commercial aircraft to reach 20% or 30% as loans for new planes become tough to get.
"In the short term, LMI has its work cut out for it over the next couple of years, given its backlog, and the advent of outsourcing by a lot of its customers will help as well," Hojo said.
LMI's total backlog at the end of 2007 was $160.9 million, up 15% from the end of 2006. Roughly $126 million is expected to be delivered in 12 months, creating good visibility, Hojo says.
Next Acquisition
As the company patrols for potential buyout targets, it will keep a few things in mind, such as acquiring a manufacturer with high-speed machining capability. It may want to make larger components on the scale of building the fuselage, which is the body of the plane, Hamilton says.
There is also a shift to a new kind of metal that requires a change in its capabilities. The next generation of commercial aircraft, including the Airbus A380 and Boeing's 787, are using more and more composite material instead of sheet metal.
As energy costs squeeze airlines, lightweight composite materials will help reduce the amount of fuel used.
"It is clear that a secular shift is occurring in the industry right now," Hamilton said. "LMI will keep all these changing factors in mind as it scours the industry for more acquisitions."
公司还为Sikorsky制造的Black Hawk直升飞机提供金属零部件产品，后者是United Technologies(代號:UTX) 旗下子公司。这些如雪片飞来的订单使得公司四季度销售额增长率达到20%以上。四季度营收飙升了91%至6490万美元。公司预计09年销售额将达到 2.89-3.04亿美元，分析师预计09年营收为2.9497亿美元。公司飞机结构板块的销售额上涨了23%至4160万美元。而技术维护部门销售额达到2400万美元。这是受到公司的商用飞机，尤其是来自BA订单的极大推动。
公司的军用飞机业务也上涨了41%至1170万美元，主要由于较高的生产率和Black Hawk带来的有业绩。商用喷气式飞机销售额上涨了24%至1410万美元，商用飞机销售额创1240万美元。二季度每股收益上涨了73%至0.45美元，分析师预计为0.39美元。不断上涨的商品和原油价格并不对公司构成多大影响，公司主要依靠的是制造业务。在确立订单的时候，成本往往被转嫁到消费者身上。
美国军方发动的针对阿富汗和伊拉克的战争使得公司获得大量军事业务。而Black Hawk就占到这部分业务中很大一部份，这种直升飞机的磨损率极高。公司还将迎来商用喷气式飞机市场需求的大涨，尤其是在BA和其它航空公司罢工斗争不断的当前。分析师表示：“上述利好因素将大大提振公司09年的业绩，预计营收将增加至少2500-3000万美元。”“就短期来看，公司已经进行了裁员和扩大的订单量的战略，同时合同业务外包也不失为一种降低成本的有效措施。”
公司截至07年底总订单量达到1.609亿美元，同比上涨了15% 。约有1.26亿美元订单能够持续12个月之久。新一轮的收购战略也在如火如荼地展开，公司正在考虑收购一家拥有高速加工能力的制造商。总而言之，分析师认为：“公司将秉承变革的理念，通过不断的收购战略实现业务多元化目标。”
Cash America典当连锁如虎添翼
10/21 02:22 EST
随着天气变冷，美国人开始涌入南部温暖宜人的度假胜地，那么他们钱包里的钞票够用吗？Cash America International(代號:CSH) 已经替您预先考虑到了这一点。就在9月29日，Cash America答应斥资9000万美元收购Prenda Facil约为80%的股权，后者是一家在墨西哥16个州拥有100多个度典当营业网点的公司。此举成为Cash America跨越Rio Grande向这家位于德州的公司展开战略合作的关键，因为这家德州企业在全美拥有超过500家典当行，如虎添翼之后，Cash America将能够与First Cash Financial(代號:FCFS)在墨西哥市场上一争高下。
Jefferies分析师Richard Shane表示，墨西哥市场的确是令人垂涎三尺的宝地，尤其是墨西哥一向有典当的传统。“墨西哥客户能够准确使用典当业务，有了他们的加入，便获得了充足的短期现金来源，将能够弥补贷款亏损。”“墨西哥市场的信贷业务是蒸蒸日上。”分析师表示墨西哥人喜欢将珠宝首饰作为间接典当品，而美国人往往将家电进行典当。不同在于，珠宝在交易的过程中不会贬值，但是家电随着更新换代频率加快将成为一堆垃圾，因此珠宝拥有极大的转售期权价值。同时，黄金利润也在不断膨胀，由06年的30.4%升至今年二季度的33% 。
而在墨西哥地区，Cash America可谓是行业霸主了。公司拥有全美3-5%的典当行。但是典当行业极为零散，即便资深人士都不清楚到底有多少典当行。Cash America的典当行数量和规模远远超过两家行业竞争对手，包括First Cash和Ezcorp(代號:EZPW)，因此公司最大的优势就在于规模的全面性和板块的集中性。尽管这三大巨头都运营典当行以及日贷款业务，但是Cash America有61%的营收都来自典当行，远高于两家同行。随着经济衰退和信贷危机日益加深，典当行的业务开始兴盛起来。“经济下滑的一开始，典当品数量将增加，因为人们需要典当财务获得资金。”“而购买典当品的需求也将攀升，因为人们对打折的二手货很感兴趣。”
分析师强调，公司的日贷款业务受累于信贷危机。二季度此版块的营收仅上涨7%，而典当行版板块营收上涨了16%。但是网上日贷款业务开始兴起，已经增长了 56% 。分析师表示，当失业率上升，日贷款业务将减少。另一个问题就是政治，有的政治家抨击贷款业务就是在掠夺财务，高利贷使得借贷者永远处于负债累累的境地。一些南部和东北部的州已经明令禁止贷款业务，另一些则在贷款利率上下功夫，诸如俄亥俄州。因此公司不得不关闭在俄亥俄州的139家门店，地区占有率缩小了 15% 。
但是最终决定性法案将在今年由全民公决后出台，因此仅凭俄亥俄州的一家之言是不成规矩的。分析师表示：“日贷款业务方面的法令类似于典当行在美国市场最初形成的阶段，这是自然演化的结果。”公司面临的另一项挑战就是气候因素，公司在休斯顿和德州的加尔维斯敦拥有71出典当行，但是受到飓风艾克的影响都关闭了。分析师认为这将使得公司三季度每股收益下降0.03-0.06美元。
总体上分析师认为公司利润增长将放缓。自05年以来每个季度的每股收益至少增长了20%。今年二季度的每股收益飙升了56%至0.67美元。但是 Thomson Reuters分析师认为面年每股收益增长率将降至5%左右。因此，预计明年的每股收益仅增长11%至3.45美元。
Investor's Business Daily
Pawnshop Chain Expands South Of Border As Economy Heads South
Monday October 20, 5:52 pm ET
Amy Reeves As the weather gets cooler, many Americans plan on heading south of the border.
Should they find themselves short of funds, Cash America International will be ready for them.
On Sept. 29, Cash America (NYSE:CSH - News) agreed to pay $90 million for an 80% stake in Prenda Facil, a pawnshop chain with 100 locations in 16 Mexican states.
It will be the first step across the Rio Grande for the Texas firm, which already owns more than 500 pawnshops in the U.S.
It will join rival Texas company First Cash Financial (NasdaqGS:FCFS - News), which has been in Mexico for some time. Jefferies analyst Richard Shane says Mexico is an attractive market because the cultural approach to pawning is traditional.
"Customers in Mexico tend to use the product appropriately, in that they come in, use it as a short-term source of cash and then redeem the loan," said Shane, whose company has done business with Cash America. "Credit there tends to be very good."
Shane says Mexicans are likelier to use jewelry as collateral, whereas Americans more often use items like home electronics. Jewelry doesn't depreciate in value the way electronics do, and also has more resale options.
Also, the profit margin on gold has been rising, from 30.4% in 2006 to 33% in the second quarter of this year, according to RBC Capital Markets.
Back in the States, Cash America is the industry leader. It owns 3% to 5% of all U.S. pawnshops.
The industry is so fragmented, even insiders are vague about how many total pawnshops exist.
Cash America's store count is bigger than that of its two main rivals, First Cash and Ezcorp (NasdaqGS:EZPW - News), put together.
The advantage comes from overall size and Cash America's concentration in the sector. All three firms run both pawnshops and payday-loan outfits. But Cash America derives more of its revenue -- 61% -- from pawnshops than its rivals do.
As the economic crisis looms and other credit vehicles collapse, pawnshops look set to thrive.
"At the outset of an economic downturn, pawned goods tend to rise in quantity as customers utilize the service to free up cash from their possessions," RBC analyst Jason Arnold wrote in his Sept. 11 initiation report. "Demand for merchandise held for disposition by pawn operators also tends to rise, as consumer demand rises for goods that can be purchased at a discount to new goods prices."
Analysts like Cash America's pawnshop emphasis because the payday-loan side is under more pressure. In the second quarter, revenue in this segment rose only 7% compared with the pawn division's 16% growth. The nascent online payday-loan business was more dynamic, however, with a 56% increase.
Analysts say that overall economic conditions do hurt the payday-loan business. When unemployment rises, there are fewer paydays to borrow toward.
Another problem is political. Some argue that this type of lending is usually predatory, with borrowers getting permanently in hock to pay off their high-interest loans.
Some Northeastern and Southern states ban such lending outright. A few others put a ceiling on interest rates. One such state is Ohio, which in May capped the rate. Ohio lets payday loan businesses take a fee of $1.08 per $100 of principal.
Cash America has been charging an average of $17.50.
The rate is so uneconomical that Cash America might have to close its 139 Ohio stores, shrinking its location count by 15%.
However, the industry managed to qualify a referendum reversing the law on this year's Ohio ballot. So analysts will have to wait until Nov. 4 to make definite future projections.
Shane is philosophical.
"What's going on in terms of payday lending regulation is similar to when the pawn product was first established in the U.S.," he said. "It's a natural evolution."
Another challenge Cash America faces is the weather. The firm has 71 locations in Houston and Galveston, Texas, the island city that Hurricane Ike closed down for two weeks in September.
Analysts will have to await the official third-quarter results Thursday to learn the extent of the damage. But they agree that it will hurt.
In a Sept. 22 note, Sterne Agee analyst Henry Coffey forecast a hit of 3 cents to 6 cents a share.
"We do not know the exact profitability of the region, and it would be wrong to assume that all of a company's stores are completely inactive," Coffey's note cautioned. "Our EPS estimates are not definitive, just educated best guesses."
Cash America did not respond to requests for comment.
Overall, analysts do expect a slowdown in the firm's profit growth. Results have been rock steady for years, with earnings rising at least 20% every quarter since 2005. In the second quarter, profit jumped 56% to 67 cents a share.
But analysts polled by Thomson Reuters see growth dwindling into the single digits over the next year, even going negative in the first quarter of 2009. For that reason, profit is expected to grow only 11% next year to $3.45 per share.
Still, the fact that Agee and Arnold launched coverage on the company in just the last two months shows that they like the industry's fundamentals.
"Demand for pawn lending and payday lending remains robust," said Shane. "I would expect solid third-quarter results, though the impact of the hurricane probably reduces the likelihood of a significant upside."
Wednesday, October 15, 2008
老道买磷
氮、磷、钾三种化肥中，目前钾最缺，这是POT的强项，但从长远来看，氮和钾几乎无限可采，只要需要世界可建更多的氮肥厂，钾肥厂，那时氮肥钾肥价格就会下降，但磷则非常有限，建不出更多的磷肥厂。其它东西你可以不用，但人总不能不吃饭，而没有磷肥，粮食产量会大幅下降，磷资源比水和石油更宝贵。而MOS是世界最大磷矿，所以老道前面买入的MOS是无论如何不会卖的。磷对人类社会的生存发展如此重要,所以引起了世界各国政府的高度重视。我国国土资源部的相关统计表明,我国磷储量位居世界第三,仅次于摩洛哥和 美国。但实际上,现有27亿吨折标磷矿储量仅够维持我国再使用70年左右的时间,其中还包含绝大部分(90%以上)非富磷矿(P2O5)(30%)。如果 仅以富磷矿磷储量(P2O5)(30%)计算,我国富磷矿储量(占总磷矿储量的8.4%)仅能维持我国使用10-15年。
更让人忧心的是,科学研究发现,磷和太阳能以及氮等元素的生物化学循环完全不同,在生物圈中,它是单向流动的,而且难以再生植物生长所需的各种 主要营养元素如氧、碳、氢、氮和磷等,它们在生物圈的生物地质化学循环中运动,形成了水(H2O)、碳(C)、氮(N)、磷(P)四大物质、元素的循环。
“磷元素却是个例外！”北京建筑工程学院可持续环境生物技术研发中心的郝晓地教授指出,在生物圈中,水(H2O)、碳(C)、氮(N)可形成物 质或元素真正的循环,中间虽有形式、形态上的变化,但可利用量基本保持不变。而磷(P)在大千世界中的循环路径完全不同,它的消耗将造成严重的流失,因而 是一种不可更新、难以替代的资源,甚至比水和石油更加宝贵。
据了解,在自然界中,磷主要以天然磷酸盐岩石、鸟粪层岩石等形式存在。磷在人工开采使用后或经天然侵蚀后,其归宿大多是通过陆地河流流入大海, 最终沉积在深海的沉积层中。沉入深海中的磷绝大部分需经相当漫长上千万甚至亿万年的地质活动后才有可能被重新提升到陆地上来,只有很少一部分通过浅海鱼类 或海鸟被带回陆地。
因此,相对于我们面临的水危机和石油危机来说,磷危机更加急迫。许多专家表示,水可以通过有效治理和管理,有望逐渐恢复水量和水质;石油资源也 完全有可能以其他能源取而代之。而潜在的磷危机的后果更加可怕,它不仅影响我国经济的持续、高速发展,而且将对人类的生存和我国社会可持续发展构成严重威胁。
Monday, October 13, 2008
1013
| Symbol | Trade | Change | Volume | Related Info | Avg Vol (3m) | Name | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| USO | 67.78 |  1.28 | 1.92% | 6,050,924 | Chart, Message, Profile, more... | 14,079,000 | United States Oil Fund, LP | ||||||||||||||||||||||
| UNG | 29.73 | 0.25 | 0.85% | 3,220,758 | Chart, Message, Profile, more... | 8,209,550 | United States Natural Gas Fund, | ||||||||||||||||||||||
| No such ticker symbol -. Try Symbol Lookup | |||||||||||||||||||||||||||||
| ECA | 43.73 | 5.08 | 13.14% | 5,799,809 | Chart, Message, Profile, more... | 5,573,660 | EnCana Corp | ||||||||||||||||||||||
| DVN | 72.88 | 12.88 | 21.47% | 9,529,823 | Chart, Message, Profile, more... | 7,495,440 | Devon Energy Corp. (New) | ||||||||||||||||||||||
| APA | 81.04 | 14.24 | 21.32% | 6,901,648 | Chart, Message, Profile, more... | 5,891,000 | Apache Corp. | ||||||||||||||||||||||
| CHK | 20.20 | 3.68 | 22.28% | 63,904,017 | Chart, Message, Profile, more... | 24,612,900 | Chesapeake Energy Corp. | ||||||||||||||||||||||
| EOG | 71.75 | 12.16 | 20.41% | 5,704,922 | Chart, Message, Profile, more... | 4,601,070 | EOG Resources, Inc. | ||||||||||||||||||||||
| CHK | 20.20 | 3.68 | 22.28% | 63,904,017 | Chart, Message, Profile, more... | 24,612,900 | Chesapeake Energy Corp. | ||||||||||||||||||||||
| RRC | 32.21 | 5.35 | 19.92% | 5,773,326 | Chart, Message, Profile, more... | 4,386,450 | Range Resources Corp | ||||||||||||||||||||||
| KWK | 11.02 | 1.97 | 21.77% | 6,877,834 | Chart, Message, Profile, more... | 3,657,710 | Quicksilver Resources, Inc. | ||||||||||||||||||||||
| SWN | 28.44 | 7.63 | 36.67% | 10,965,793 | Chart, Message, Profile, more... | 7,439,000 | Southwestern Energy Company | ||||||||||||||||||||||
| FST | 28.85 | 5.27 | 22.35% | 3,216,230 | Chart, Message, Profile, more... | 1,954,180 | Forest Oil Corp. | ||||||||||||||||||||||
| No such ticker symbol -. Try Symbol Lookup | |||||||||||||||||||||||||||||
| GDP | 28.27 | 7.30 | 34.81% | 1,931,654 | Chart, Message, Profile, more... | 1,848,500 | Goodrich Petroleum Corp. (Holdi | ||||||||||||||||||||||
| HK | 13.60 | 3.96 | 41.08% | 12,356,485 | Chart, Message, Profile, more... | 10,185,700 | Petrohawk Energy Corp | ||||||||||||||||||||||
| GMXR | 31.14 | 7.89 | 33.94% | 694,683 | Chart, Message, Profile, more... | 649,950 | GMX RESOURCES INC | ||||||||||||||||||||||
| CRK | 36.10 | 7.80 | 27.56% | 1,264,937 | Chart, Message, Profile, more... | 1,562,120 | Comstock Resources, Inc. | ||||||||||||||||||||||
| No such ticker symbol -. Try Symbol Lookup | |||||||||||||||||||||||||||||
| ATN | 18.73 | 3.36 | 21.86% | 226,015 | Chart, Message, Profile, more... | 334,350 | Atlas Energy Resources LLC | ||||||||||||||||||||||
| No such ticker symbol -. Try Symbol Lookup | |||||||||||||||||||||||||||||
| CLB | 82.88 | 12.70 | 18.10% | 546,100 | Chart, Message, Profile, more... | 372,135 | Core Laboratories N.V. (Netherl | ||||||||||||||||||||||
| GTLS | 18.92 | 1.87 | 10.97% | 956,773 | Chart, Message, Profile, more... | 495,012 | CHART INDUSTRIES, IN | ||||||||||||||||||||||
| NOV | 29.14 | 5.72 | 24.42% | 20,555,970 | Chart, Message, Profile, more... | 9,399,320 | National Oilwell Varco Inc | ||||||||||||||||||||||
| CAM | 30.78 | 5.54 | 21.95% | 6,094,216 | Chart, Message, Profile, more... | 4,628,900 | Cameron International Corp | ||||||||||||||||||||||
| FTI | 39.95 | 5.32 | 15.36% | 4,312,568 | Chart, Message, Profile, more... | 2,400,540 | FMC Technologies, Inc. | ||||||||||||||||||||||
| TTES | 25.68 | 6.71 | 35.37% | 276,834 | Chart, Message, Profile, more... | 233,517 | T-3 ENERGY SVCS | ||||||||||||||||||||||
| NCL | 9.1132 | 1.3432 | 17.29% | 21,933 | Chart, Message, Profile, more... | 18,931.8 | Nuveen Insured California Premi | ||||||||||||||||||||||
| HP | 30.50 | 6.39 | 26.50% | 3,531,010 | Chart, Message, Profile, more... | 1,980,770 | Helmerich & Payne, Inc. | ||||||||||||||||||||||
| No such ticker symbol -. Try Symbol Lookup | |||||||||||||||||||||||||||||
| FLS | 67.90 | 11.58 | 20.56% | 2,195,704 | Chart, Message, Profile, more... | 1,375,500 | Flowserve Corp. | ||||||||||||||||||||||
| RBN | 25.69 | 3.51 | 15.83% | 602,630 | Chart, Message, Profile, more... | 651,791 | Robbins & Myers, Inc. | ||||||||||||||||||||||
| CFX | 9.91 | 1.46 | 17.28% | 647,742 | Chart, Message, Profile, more... | 392,711 | COLFAX CORPORATION | ||||||||||||||||||||||
| SNHY | 24.13 | 2.71 | 12.65% | 215,086 | Chart, Message, Profile, more... | 179,427 | SUN HYDRAULICS COR | ||||||||||||||||||||||
| TISI | 31.72 | 2.66 | 9.15% | 311,105 | Chart, Message, Profile, more... | 199,361 | TEAM INC | ||||||||||||||||||||||
| No such ticker symbol -. Try Symbol Lookup | |||||||||||||||||||||||||||||
| PBR | 34.00 | 7.90 | 30.27% | 39,460,282 | Chart, Message, Profile, more... | 23,809,000 | Petroleo Brasileiro S.A. | ||||||||||||||||||||||
| HES | 59.22 | 6.30 | 11.90% | 9,563,360 | Chart, Message, Profile, more... | 5,466,130 | Hess Corp | ||||||||||||||||||||||
| DVN | 72.88 | 12.88 | 21.47% | 9,529,823 | Chart, Message, Profile, more... | 7,495,440 | Devon Energy Corp. (New) | ||||||||||||||||||||||
| No such ticker symbol -. Try Symbol Lookup | |||||||||||||||||||||||||||||
| SSL | 29.85 | 4.85 | 19.40% | 1,415,721 | Chart, Message, Profile, more... | 1,007,790 | SASOL LTD ADR | ||||||||||||||||||||||
| No such ticker symbol -. Try Symbol Lookup | |||||||||||||||||||||||||||||
| CLR | 25.90 | 5.84 | 29.11% | 2,087,951 | Chart, Message, Profile, more... | 2,254,450 | CONTINENTAL RESRCES | ||||||||||||||||||||||
| HES | 59.22 | 6.30 | 11.90% | 9,563,360 | Chart, Message, Profile, more... | 5,466,130 | Hess Corp | ||||||||||||||||||||||
| EAC | 25.59 | 5.33 | 26.31% | 1,406,694 | Chart, Message, Profile, more... | 1,279,880 | Encore Acquisition Co. | ||||||||||||||||||||||
| WLL | 45.45 | 8.95 | 24.52% | 1,392,781 | Chart, Message, Profile, more... | 1,271,120 | Whiting Petroleum Corp (New) | ||||||||||||||||||||||
| SM | 25.15 | 4.43 | 21.38% | 1,047,306 | Chart, Message, Profile, more... | 1,341,800 | St. Mary Land & Exploration Co. | ||||||||||||||||||||||
| EOG | 71.75 | 12.16 | 20.41% | 5,704,922 | Chart, Message, Profile, more... | 4,601,070 | EOG Resources, Inc. | ||||||||||||||||||||||
| BEXP | 6.82 | 1.33 | 24.23% | 1,192,902 | Chart, Message, Profile, more... | 1,176,940 | BRIGHAM EXPLORATN | ||||||||||||||||||||||
| NOG | 4.67 | 0.37 | 8.60% | 276,020 | Chart, Message, Profile, more... | 410,459 | NORTHERN OIL AND GAS | ||||||||||||||||||||||
| No such ticker symbol -. Try Symbol Lookup | |||||||||||||||||||||||||||||
| WES | 12.88 | 0.97 | 8.14% | 191,694 | Chart, Message, Profile, more... | 171,080 | WESTERN GAS PARTNERS | ||||||||||||||||||||||
| WHX | 14.04 | 1.29 | 10.12% | 109,280 | Chart, Message, more... | 128,536 | WHITING USA TRUST I | ||||||||||||||||||||||
| PSE | 14.95 | 3.03 | 25.42% | 99,821 | Chart, Message, Profile, more... | 6,917,880 | PIONEER STHWST ENERG | ||||||||||||||||||||||
| No such ticker symbol -. Try Symbol Lookup | |||||||||||||||||||||||||||||
| HEV | 7.65 | 0.16 | 2.14% | 265,306 | Chart, Message, Profile, more... | 535,858 | ENER1 INC | ||||||||||||||||||||||
| MXWL | 9.81 | 0.10 | 1.03% | 234,220 | Chart, Message, Profile, more... | 140,292 | MAXWELL TECHS INC | ||||||||||||||||||||||
| No such ticker symbol -. Try Symbol Lookup | |||||||||||||||||||||||||||||
| OKE | 30.13 | 6.96 | 30.04% | 2,017,311 | Chart, Message, Profile, more... | 927,145 | Oneok Inc. (New) | ||||||||||||||||||||||
| EP | 9.00 | 1.78 | 24.65% | 18,293,426 | Chart, Message, Profile, more... | 11,538,700 | El Paso Corp. | ||||||||||||||||||||||
| COP | 56.24 | 8.01 | 16.61% | 29,467,654 | Chart, Message, Profile, more... | 14,994,900 | ConocoPhillips | ||||||||||||||||||||||
| COG | 26.88 | 5.57 | 26.14% | 3,393,077 | Chart, Message, Profile, more... | 3,135,440 | Cabot Oil & Gas Corp. | ||||||||||||||||||||||
| APA | 81.04 | 14.24 | 21.32% | 6,901,648 | Chart, Message, Profile, more... | 5,891,000 | Apache Corp. | ||||||||||||||||||||||
| No such ticker symbol -. Try Symbol Lookup | |||||||||||||||||||||||||||||
| TS | 29.30 | 5.20 | 21.58% | 3,849,011 | Chart, Message, Profile, more... | 3,253,290 | Tenaris SA | ||||||||||||||||||||||
| WH | 5.20 | 0.50 | 10.64% | 147,508 | Chart, Message, Profile, more... | 125,777 | WSP HOLDINGS LTD ADS | ||||||||||||||||||||||
| SMS | 15.30 | 1.80 | 13.33% | 300,264 | Chart, Message, Profile, more... | 415,461 | Sims Group Ltd | ||||||||||||||||||||||